GENE ONLINE|News &
Opinion
Blog

COVID-19: Targeting Better Efficacy, China Trials Mixing CanSino and Zhifei Longcom Vaccines

by Tyler Chen
Share To

Under the pressing need for more effective COVID-19 vaccinations, China has begun examining the efficacy of mixing two approved vaccines. The country is evaluating the combination of CanSino Biologics’ Ad5-nCoV (Convidecia) and Anhui Zhifei Longcom Biopharmaceuticals’ ZF2001 (RBD-Dimer).

Efficacy Evaluations in Two Interval Settings

Sponsored by the Jiangsu province centers for disease control and prevention in China, the trial recruited 120 healthy subjects who received one dose of Ad5-nCoV on day 0. Then, half of the subjects will receive a booster dose of either ZF2001 or trivalent split influenza vaccine on day 28 with the ratio of 2:1; the other half will be put under the same regime but with the interval of 56 days.

Scientists will primarily look at the incidence of solicited adverse events within 7 days after vaccination and geometric mean titer (GMT) of neutralizing antibodies against SARS-CoV-2 at day 14 after the booster vaccination. The trial will last for 6 months according to the clinical records on ClinicalTrials.gov.

Ad5-nCoV: 68% Efficacy with One Shot

Ad5-nCoV is the only single shot COVID-19 vaccine to be approved in China. As stated in the interim report of a Phase 3 clinical trial, the vaccine registered a 68.83% efficacy 14 days after administration. In 28 days, the number fell to 65.28%.

Currently, the vaccine is not approved in the US, but it has been granted accelerated approval in five countries, including China, Chile, Mexico, Pakistan, and Hungary. The five vaccines that are currently approved in China are all locally developed and produced.

CanSino Pushes for Inhaled Vaccine

According to Co-Founder and Chief Executive Officer Xuefeng Yu, CanSino Biologics is now working on an inhaled version of its COVID-19 vaccine with the help of the Beijing Institute of Biotechnology. An inhaled vaccine might add more protection than an injected one considering the airway is the first stop of SARS-CoV-2 entering the body. The clinical trial is expected to begin next week.

With that, CanSino Biologics will have a chance to compete with the global vaccine market since Pfizer/BioNTech, Moderna, AstraZeneca, and Johnson & Johnson vaccines demonstrated stronger protection than Ad5-nCoV.

Related Article: The Accessibility of Point-of-Care COVID-19 Detection Tests: Why Care?

 

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
GeneOnline’s Weekly News Highlights: Sept 17-Sept 22
2023-09-26
GeneOnline’s Weekly News Highlights: Sept 11-Sept 15
2023-09-19
U.S. Government Awards $1.4 Billion to Advance COVID Therapies and Vaccines
2023-08-29
LATEST
Previewing AACR 2024 With Select Pre-Meeting Highlights
2024-03-28
Roche Delivering on Malaria Screening Solutions for Blood Donation
2024-03-28
Innovating Cancer Treatment: The Role of ADC Technology at Nona Biosciences
2024-03-28
BIO CHINA 2024 Brings Biotech Experts and Industry Elites Together for Innovation
2024-03-27
Galderma’s Strong European IPO Debut
2024-03-26
Markets and Mergers: Boston Scientific and Axonics Shake Hands on Deal
2024-03-25
Discover the Next Billion-Dollar Unicorn at the Biotech Innovation Funding Networking Event
2024-03-21
EVENT
2024-04-06
Biotech Innovation Funding Networking
Los Angeles, USA
Scroll to Top